Viridian Therapeutics, Inc.
NASDAQ:VRDNBiotechnology
-$0.15 today
- Market cap
- $3.57B
- Beta
- 0.90
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$3.53
Volume 4.02M
Average 2.86M
Returns on capital
Viridian Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.4%
avg 279.3%
ROIC
-43.8%
avg -266.7%
ROA
-38.1%
avg -81.8%
Analysis
ROA is currently the strongest return metric at -38.1% versus its period average of -81.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Stephen F. Mahoney | Chief Executive Officer, President & Director | USD 1.34M | 55 | 33.35K | 0.04% |
Thomas W. Beetham | Chief Operating Officer | USD 972.98K | 56 | 13.36K | 0.01% |
Radhika Tripuraneni | Chief Medical Officer | USD 840.69K | 46 | 0 | <0.01% |
Jennifer Tousignant | Chief Legal Officer & Corporate Secretary | USD 819.95K | 53 | 0 | <0.01% |
Seth Harmon | Chief Financial Officer | USD 785.65K | 45 | 7.85K | <0.01% |
Melissa Manno | Chief Human Resources Officer | — | — | — | — |
Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board | — | — | — | — |
Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member | — | 86 | — | — |
Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board | — | 81 | — | — |
Vahe Bedian | Co-Founder & Scientific Advisor | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 19, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$20.00M
Sells
2
$315,795.52
Net Transaction Value
+$19.68M
Net buying
Most Active
Tousignant Jennifer
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 19, 26Aug 19, 2026 | Tousignant Jennifer Direct | Sell | $245K$245,000.00 |
| May 11, 26May 11, 2026 | Fairmount Funds Management LLC Indirect | Buy | $20M$19,999,990.00 |
| Dec 31, 25Dec 31, 2025 | Tousignant Jennifer Direct | Sell | $70.8K$70,795.52 |
Summary
Insiders reported 1 buys worth $20.00M and 2 sells worth $315,795.52 over the last 12 months. That adds up to net buying of $19.68M. Tousignant Jennifer was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +241.9% | +78.8% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +241.9% over three years. Forward estimates point to Revenue at +78.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Viridian Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about VRDN's management, answered from reported figures.
Who manages VRDN?
Viridian Therapeutics, Inc. (VRDN) lists 10 active executives. The top listed executive is Jennifer Tousignant, Chief Legal Officer & Corporate Secretary.
Are VRDN insiders buying or selling?
Recent insider activity shows net buying of $248.46M.
Continue the stock analysis
Jump to another research area for this company.